Waters Surges to Top-Traded Stock as Earnings Recovery Gains Momentum

Market Snapshot

On April 2, 2026, shares of Waters Corporation (WAT) rose by 1.45%, outperforming the broader market. The stock’s trading volume surged to $0.22 billion, making it the top-traded stock of the day. Despite the positive price movement, the stock had previously shown volatility, including a sharp 14.49% pre-market drop following its Q4 2025 earnings report in February. This recent gain marked the fourth consecutive day of positive returns for WAT, signaling a potential short-term recovery trend.

Key Drivers

Waters’ Q4 2025 earnings report, released on February 9, 2026, revealed that the company exceeded expectations in both adjusted earnings per share (EPS) and revenue. It posted adjusted EPS of $4.53 against an expected $4.51 and revenue of $932 million, surpassing the forecast of $928.09 million. Despite these positive results, the stock initially dropped 14.49% in pre-market trading, indicating a possible overreaction from investors or a divergence between short-term market sentiment and the company’s long-term fundamentals.

The report highlighted 7% year-over-year revenue growth, driven by strong performance in core product lines such as the Alliance iS HPLC and Xevo TQ Absolute platforms. Additionally, Waters reported full-year adjusted EPS growth of 11% to $13.13 for 2025, suggesting solid operational momentum. The recent acquisition of BD’s Biosciences and Diagnostic Solutions further positioned Waters for long-term growth, with the new segment expected to contribute $3 billion in annual revenue. This strategic expansion underscores Waters’ ambitions to strengthen its position in the life sciences sector.

Looking ahead, Waters projected organic constant currency revenue growth of 5.5–7% for 2026, setting a total revenue range of $6.405–6.455 billion and adjusted EPS guidance of $14.30–14.50. CEO Udit Batra emphasized the significance of the BD acquisition, calling it a move to "create a scientific powerhouse." He also described the midpoint of the revenue growth forecast as "appropriately prudent, yet industry-leading," signaling confidence in the company’s strategic direction and execution capabilities.

In previous quarters, Waters has displayed a consistent ability to outperform expectations. For example, in Q3 2025, it exceeded revenue forecasts by 2.43% and delivered a 5.92% EPS surprise. In contrast, the 2026 Q1 forecast, set for May 12, is currently undefined in terms of EPS and revenue, leaving some uncertainty for investors. While the company has demonstrated resilience in earnings performance, the market appears to be weighing heavily on the long-term sustainability of its growth and integration challenges from the BD acquisition.

The recent stock performance also reflects a broader market environment. On April 2, while the S&P 500 inched up 0.11%, the Dow Jones Industrial Average declined by 0.13%. Waters’ 1.45% gain placed it among the stronger performers of the day, particularly against the backdrop of a mixed market session. The four-day winning streak for WAT suggests a short-term reversal of the post-earnings selloff, which may indicate stabilizing investor confidence or a reassessment of the company’s strategic moves.

Taken together, Waters’ earnings results, acquisition activity, and forward guidance present a complex picture of growth potential and execution risk. The market’s reaction has been mixed, with recent outperformance potentially signaling a shift in sentiment, albeit in a relatively narrow timeframe. As the company works through the integration of BD and meets its 2026 financial targets, investors will likely continue to evaluate whether the stock is overvalued or undervalued in the context of its strategic vision and competitive position.